b'Hematological Test MenuDiseases Gene Rearrangement Translocation MutationsRecommended IGHIGHIGKIGLIGHVTRBTRDTRGIGH-IGH-BCR-PMLFLT3NPM1 Primary Test V H- J H D H- J H SHMBCL1BCL2 ABL1*RAR*Hematological Test Recommended (CCND1)Secondary TestMarginal Zone Lymphoma(MZL), extranodal 12,13,2788% 58% 84% 29% 23% 10% 16% Menu References Marginal Zone Lymphoma(MZL), nodal 13100% 30% 80% 30% 10% 20% 10% Mantle Cell Lymphoma (MCL) 2,6,7,12,13,27,37100% 11% 100% 44% * 9% 4% 11% 75%Follicular Lymphoma (FL) 3,7,12,13,27,2884% 19% 84% 21% 6% 5% 2% 90%Diffuse Large B-cell Lymphoma80% 30% 80% 28% 21% 14% 15% 30%(DLBCL) 3,12,13,27Multiple Myeloma (MM) and other Plasma Cell Neoplasms (PCN) 2,9,10,20,2584% 60% 57% 97% 20% Chronic Lymphocytic Leukemia (CLL) 11,12,13,15,23,27,35100% 43% 100% 30% * 25% 12% 18% Lymphoid/ LymphomaB-cell Acute LymphoblasticLeukemia (B-ALL) 4,12,14,19,21,22,27,29,30,31,32,33,3496% 57% 95% 20% 81% 86% 75% 30%Suspect B-cell Proliferations 12,26,27,3393% 93% 90% 40% 20% 20%Peripheral T-cell Lymphoma35% 4% 2% 98% 94%(PTCL) 12,13,14,241. Kakizuka, A et al. (1991) Cell, 66:675-684. 17. Huang, W et al. (1993) Blood, 82:1264-1269. 30. Szczepanski, T et al. (2001) Leukemia,2. Rimokh, R et al. (1994) Blood, 83:1871-1875. 18. Hughes, T et al. (2006) Blood, 108:28-37. 15:14151423.T-cell Acute Lymphoblastic Leukemia4% 31. Szczepanski, T et al. (1998) Leukemia,(T-ALL) 12,14,21,22,29,3124% 25% 92% 68% 95% 3. Gribben, JG et al. (1994) Blood, 83:3800-3807. 19. Westbrook, CA et al. (1992) Blood, 80:2983-2990. 12:10811088.4. Radich, JP et al. (1994) Leukemia, 8:1688-1695. 20. Ralph, QM et al. (1993) Blood, 82:202-20. 32. Beishuizen, A et al. (1994) Leukemia,Angioimmunoblastic T-cellLymphoma (AILT) 12,13,1419% 11% 30% 5% 99% 35% 92% 5. Gallagher, RE et al. (1995) Blood, 86:1540-1547. 21. Jurez-Velzquez, MR et al. (2013) Clinical 8(12):2228-36.6. De Boer, CJ et al. (1995) Blood, 86:2715-2723.Epidemiology of Acute Lymphoblastic Leukemia - 33. Tmkaya T et al. (2001) Leukemia, 15:121127. From the Molecules to the Clinic, 193-235.Adult T-cell Leukemia/Lymphoma 3997% 96% 7. Deininger, MW et al. (2000) Blood, 96:3343-56. 34. Felix, CA et al. (1990) J Clin Oncol., 8(3):431-42.22. Raimondi, S. (2007) Atlas Genet Cytogenet 8. Schlenk RF et al. (2008) N Engl J Med., Oncol Haematol., 11(4):328-339. 35. Rosenquist R et al. (2017) Leukemia, 31:14771481.Anaplastic Large-Cell Lymphoma358:1909-1918.(ALCL) 12,13,1474% 12% 74% 23. Vardi, A et al. (2015) Clin Cancer Res., 22(1):167-36. Arons, E et al. (2011) Blood, 117(18): 48444851.9. Gonzalez, D et al. (2003) Leukemia, 17:1051-1057. 174. 37. Lai, R et al. (2006) Modern Pathology,10. Gonzalez, D et al. (2003) Leukemia, 17:1398-1403. 24. Tan, BT et al. (2008) J Mol Diag., 10(6):502512. 19:14981505.T-cell Prolymphocytic Leukemia3% 3% 3% 3% 100% 6% 94%(T-PLL) 12,13,1411. Ghia, P et al. (2007) Leukemia, 21:1-3. 25. Gonzlez, D et al. (2007) Blood, 110:3112-3121. 38. Srour SA et al. (2017) Br J Haematol., 177(2): 331. T-cell Large Granular Lymphocytic12. van Krieken, JH et al. (2007) Leukemia, 21:201-6. 26. Langerak AW et al. (2007) Exp Opin Med Diag., 39. Ohshima, K et al. (1990) Hematol Oncol.,Leukemia (T-LGL Leukemia) 12,13,144% 4% 97% 29% 96% 1(4):451-461. 8(2):111-8.13. Evans, PAS et al. (2007) Leukemia, 21:207-214.14. Bruggemann, M et al. (2007) Leukemia, 21:215- 27. Arcila, ME et al. (2019) J Mol Diag., 2: 330-341. 40. van Dongen, JJM et al. (2003) Leukemia, 17,Suspect T-Cell Proliferations 12,26,4010% 10% 90% 11% 90% 221. 28. Campo, E et al. (2011) Blood, 117(19): 50195032.22572317. 15. Davi, F et al. (2008) Leukemia, 22:212-214. 29. Smirnova, SY et al. (2016) Acta naturae,Acute Myeloid Leukemia (AML) 8,1633% 64% 16. Dhner, H et al. (2010) Blood, 115:453-474. 8(4):100109.Acute Promyelocytic Leukemia (APL) 1,5,16,1790%Myeloid Chronic Myeloid Leukemia (CML) 7,18,19,21,3887%Myeloproliferative NeoplasmsNOTICE: *Some translocation assays, LymphoTrack, and MRD applications are currently Research Use Only; not for use in diagnostic procedures. Illumina and (MPNs) 38 10% MiSeq are registered trademarks of Illumina, Inc. Ion S5TM and Ion PGMTM are trademarks of Thermo Fisher Scientific.Note: The percentage of samples within a given disease category were detected using each gene target. Percentages indicate the highest referenced value. 2021 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its aliates or (as the trademarks of others used herein) their respective owners.20Invivoscribe 2021|21'